An important new adaption of a specific drug?

Manno, Massimo; Tomei, Francesco; Marchesan, E.; Adamo, Valter

doi:10.1016/j.fertnstert.2007.03.025

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cabergoline has been reported to effectively prevent OHSS in high-risk patients. Although several studies showed that cabergoline prevented the occurrence of OHSS [7,39], in one study 11.4 % of patients developed severe OHSS [4]. Even if cabergoline was combined with coasting, severe OHSS still occurred in patients with extremely high serum E 2 levels (>9,000 pg/ml) [31].…”

Section: Introductionmentioning

confidence: 92%

Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels—a retrospective study

Lin¹,

Huang

Hwang

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 92%

Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels—a retrospective study

Lin¹,

Huang

Hwang

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Although the pathophysiology is not fully understood, vascular endothelial growth factor (VEGF) has been proposed to be the key mediator [2]. Several studies have shown that cabergoline, which antagonizes VEGF effect on vascular permeability, effectively prevented OHSS [2][3][4]. We report two patients at high risk for OHSS who developed the complication despite undergoing combined treatment with coasting and cabergoline.…”

mentioning

confidence: 99%

Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients with extremely high estradiol levels

Hwang

Lin

Seow

2009

Intl J Gynecology & Obste

View full text Add to dashboard Cite

between the rCL and the non-rCL groups were analyzed, as appropriate, with t tests or Mann-Whitney U tests. P < 0.05 was considered statistically significant.Two women were excluded from the analysis because of corpus luteum persistence-as defined by serum progesterone levels of 2 ng/ mL or more on D1-before receiving rhCG. Rescued corpus luteum occurred in 19 (67.9%) of the remaining 28 participants, with the other 9 (32.1%) classified as having non-rCL. Serum progesterone and estradiol levels following rhCG administration were significantly greater in the rCL group than in the non-rCL group (P < 0.01; Table 1).Serum levels of FSH and LH did not differ significantly between the groups on D1 or D3.Rescued corpus luteum was observed in a surprisingly large proportion-approximately two-thirds-of women undergoing ovulation induction with a GnRH antagonist who received a single pharmacophysiologic dose of rhCG on D1. Although rCL was not a universal feature among women who were administered rhCG on D1, efforts to limit its occurrence should be made to prevent the possible harmful effects on IVF outcome of a premature increase in progesterone levels.

show abstract

Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis

Youssef

Wely

Hassan

et al. 2010

Human Reproduction Update

View full text Add to dashboard Cite

show abstract

An important new adaption of a specific drug?

Cited by 3 publications

References 5 publications

Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels—a retrospective study

Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels—a retrospective study

Failure of cabergoline to prevent severe ovarian hyperstimulation syndrome in patients with extremely high estradiol levels

Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis

Contact Info

Product

Resources

About